

Special Issue

Pandemics-Born Revolution in the Preclinical and Clinical Trials of Microbial Vaccines

Message from the Guest Editors

This issue is welcoming submissions of experimental papers, short communications, reviews and activity reports focusing on the above problems. We specifically welcome submissions which consider the impact of SARS-CoV-2 pandemics on:

- Development of plug and play platforms approach
- Future vaccine discovery/development; harnessing the current momentum for vaccine development to create new vaccine platforms
- Novel vaccines/technologies for accommodating emerging SARS-CoV-2 variants
- Novel vaccines/technologies against other common and emerging (re-emerging) pathogens
- Development of animal models to test vaccine efficacy
- Vaccine manufacture and upscale in the future
- Formulations that aid the stability of vaccines facilitating distribution to less accessible and low resource countries

Guest Editors

Dr. Maria G. Isaguliantz

Prof. Dr. Felicity Jane Burt

Dr. Ilya Gordeychuk

Deadline for manuscript submissions

closed (31 August 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/129976

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).